PMPRB Summary of VCUs & Orders - 2008
Click on medicine to view details of VCU
| DATE OF APPROVAL |
MEDICINE |
PATENTEE |
%Above Guidelines |
PRICE REDUCTION1 |
EXCESS REVENUES2 |
PAYMENTS |
PATENT STATUS |
| VCUs |
| June 24, 2008 |
AndroGel |
Solvay Pharma Inc. |
See VCU |
Yes |
$3,327,180.61 |
$3,327,180.61 |
Expiration August 29, 2021 |
| May 20, 2008 |
Denavir |
Barrier Therapeutics Canada Inc. |
See VCU |
Yes |
$61,021.80 |
$61,021.80 |
Expiration July 3, 2012 |
| March 4, 2008 |
Lantus |
sanofi-aventis Canada Inc. |
See VCU |
Yes |
$3,969,554.833 |
$694,239.50 |
Patent # 2,050,644 – Expiration : 09/2011
Patent # 1,340,237 – Expiration : 08/2008
Patent # 1,339,044 – Expiration : 09/2009 |
| February 28, 2008 |
Vaniqa |
Barrier Therapeutics Canada Inc. |
14% |
Yes |
$70,860.59 |
$70,860.59 |
05/2013 |
| ORDER |
1.There are no price reductions in cases where the PMPRB's jurisdiction ceased with the expiry or the dedication (prior to 1995) of the patent.
2. In all cases, all excess revenues were offset through further price reduction and/or payment.3. Notice of Hearing issued on January 30, 2006.
3.To offset the cumulative excess revenues received from January 1, 2007 to the date of the price reduction, sanofi-aventis agrees to reduce the price of ALTACE HCTR (DINs 2283131, 2283158, 2283166, 2283174, 2283182). In the event that the full amount of excess revenues is not offset by December 31, 2008, sanofi-aventis will undertake to offset the amount by making a further payment to Her Majesty in Right of Canada.